GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft
Comparison of Primary Patency Between GORE PROPATEN Vascular Graft and Disadvantaged Autologous Vein Graft For Below-Knee Arterial Bypass (PRODIGY Study)
Sponsor: W.L.Gore & Associates
Listed as NCT00617279, this PHASE4 trial focuses on Peripheral Arterial Occlusive Disease and remains terminated or withdrawn. Sponsored by W.L.Gore & Associates, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- W.L.Gore & Associates
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Atlanta, United States, Baltimore, United States, Baton Rouge, United States, Birmingham, United States, Boston, United States, Chicago, United States, Cleveland, United States, Greenville, United States, Houston, United States and 7 more location s